FOXO4-DRI (Proxofim): A Peptide Senolytic Targeting Cellular Senescence for Longevity and Disease Treatment
Discover the groundbreaking potential of FOXO4-DRI, a peptide that unlocks cellular rejuvenation by targeting senescent cells.
Get a Quote & SampleProduct Core Value
FOXO4-DRI
FOXO4-DRI, also known as Proxofim, is a cell-permeable peptide antagonist that precisely targets and disrupts the interaction between FOXO4 and p53. This targeted action makes it a potent senolytic agent, capable of inducing apoptosis in senescent cells while leaving healthy cells unharmed. Its ability to block the FOXO4-p53 interaction is key to its efficacy in various therapeutic applications.
- Understanding the FOXO4-DRI peptide mechanism reveals its crucial role in cellular aging processes.
- Buy FOXO4-DRI wholesale to leverage its unique properties for advanced research and development.
- This senescence reversal peptide offers a novel approach to combat age-related decline and disease.
- Explore the benefits of longevity peptides like FOXO4-DRI for extending healthspan.
Key Advantages
Targeted Senescent Cell Elimination
FOXO4-DRI selectively targets and eliminates senescent cells, a critical factor in combating age-related diseases and promoting tissue regeneration.
Promotes Longevity
By clearing senescent cells, FOXO4-DRI contributes to improved tissue function and potentially extends healthspan, aligning with goals for enhanced longevity.
Therapeutic Potential
This peptide holds significant promise for treating various aging-related conditions, including cardiovascular and neurodegenerative diseases, and as an adjunct in cancer therapy.
Key Applications
Senescence Reversal
FOXO4-DRI effectively reverses cellular senescence by inducing apoptosis in aged cells, a key step in rejuvenating tissues.
Longevity Research
As a powerful tool in longevity research, this peptide helps in understanding and manipulating the aging process at a cellular level.
Aging-Related Disease Treatment
Its ability to clear senescent cells offers a new therapeutic avenue for conditions such as cardiovascular and neurodegenerative diseases.
Cancer Therapy Adjunct
Research indicates potential for FOXO4-DRI to improve cancer treatment efficacy by targeting senescent cells within the tumor microenvironment.